Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.
Cantor Fitzgerald analyst Josh Schimmer upgrades 4D Molecular Therapeutics (NASDAQ:FDMT) from Neutral to Overweight and announces $20 price target.